{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:46:34Z","timestamp":1787168794740,"version":"build-2736575974"},"reference-count":81,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Mantle cell lymphoma (MCL) is a mature B\u2010cell lymphoma with a variable clinical course and historically poor prognosis. Management is challenging in part due to the heterogeneity of the disease course, with indolent and aggressive subtypes now well recognised. Indolent MCL is often characterised by a leukaemic presentation, SOX11 negativity and low proliferation index (Ki\u201067). Aggressive MCL is characterised by rapid onset widespread lymphadenopathy, extra\u2010nodal involvement, blastoid or pleomorphic histology and high Ki\u201067. Tumour protein p53 (\n                    <jats:italic>TP53<\/jats:italic>\n                    ) aberrations in aggressive MCL are recognised with clear negative impact on survival. Until recently, trials have not addressed these specific subtypes separately. With the increasing availability of targeted novel agents and cellular therapies, the treatment landscape is constantly evolving. In this review, we describe the clinical presentation, biological factors, and specific management considerations of both indolent and aggressive MCL and discuss current and potential future evidence which\u00a0may help move to a more personalised approach.\n                  <\/jats:p>","DOI":"10.1111\/bjh.18697","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T23:49:38Z","timestamp":1676936978000},"page":"185-198","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["How I manage mantle cell lymphoma: indolent versus aggressive disease"],"prefix":"10.1111","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-3270","authenticated-orcid":false,"given":"Matthew R.","family":"Wilson","sequence":"first","affiliation":[{"name":"Beatson West of Scotland Cancer Centre  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Barrett","sequence":"additional","affiliation":[{"name":"Haematology and Cancer Centre Oxford University Hospitals National Health Service (NHS) Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-1565","authenticated-orcid":false,"given":"Chan Yoon","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Haematology, Sir Charles Gairdner Hospital  Perth Western Australia Australia"},{"name":"Division of Internal Medicine University of Western Australia  Perth Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9749","authenticated-orcid":false,"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[{"name":"Haematology and Cancer Centre Oxford University Hospitals National Health Service (NHS) Foundation Trust  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx333"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.201350"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01988.x"},{"issue":"3","key":"e_1_2_13_6_1","first-page":"1042","article-title":"Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature","volume":"7","author":"Hsu P","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.052621"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00394-z"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2002317"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.135"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2019.04.010"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036277"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400580"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1864"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1615"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005289"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151649"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30068"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128340"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1455973"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9731"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-585067"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01797"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02321"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015560"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-737502"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001396"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_13_36_1","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar A","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26523"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.162"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153283"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150181"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00638-0"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205229"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00195-2"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02698"},{"key":"e_1_2_13_58_1","unstructured":"DreylingM DoorduijnJK GineE JerkemanM WalewskiJ HutchingsM.Efficacy and safety of Ibrutinib combined with standard first\u2010line treatment or As substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized Triangle trial by the European MCL network. Presented at 64th ASH annual meeting and exposition December 2021."},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.825906"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04506-y"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15723"},{"key":"e_1_2_13_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15721"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01418-3"},{"key":"e_1_2_13_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01288-9"},{"key":"e_1_2_13_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_2_13_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"e_1_2_13_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17513"},{"key":"e_1_2_13_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151831"},{"key":"e_1_2_13_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160459"},{"key":"e_1_2_13_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114110"},{"key":"e_1_2_13_71_1","unstructured":"WangML ShahNN JurczakW ZinzaniPL EyreTA CheahCY.Efficacy of Pirtobrutinib in covalent BTK\u2010inhibitor pre\u2010treated relapsed \/ refractory mantle cell lymphoma: additional patients and extended follow\u2010up from the phase 1\/2 BRUIN study. 64th ASH annual meeting and exposition. Presented at 64th ASH annual meeting and exposition December 2021."},{"key":"e_1_2_13_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_13_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"},{"key":"e_1_2_13_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147563"},{"key":"e_1_2_13_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006922"},{"key":"e_1_2_13_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165031"},{"key":"e_1_2_13_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18378"},{"key":"e_1_2_13_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157777"},{"key":"e_1_2_13_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_13_80_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198812"},{"key":"e_1_2_13_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25796"},{"key":"e_1_2_13_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01188-x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.18697","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T15:16:00Z","timestamp":1692544560000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/bjh.18697"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18697","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"2022-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}